Khanh Bao Tran1,2, Grégory Gimenez3,2, Peter Tsai1, Sharada Kolekar4,1, Euan J. Rodger3,2, Aniruddha Chatterjee3,2, Anower Jabed1, Jen‐Hsing Shih1, Wayne R. Joseph4, Elaine S. Marshall4, Qian Wang1, Cristin G. Print1,2, Michael R. Eccles3,2, Bruce C. Baguley4, Peter R. Shepherd4,1,2
1Department of Molecular Medicine and Pathology, University of Auckland, Auckland, New Zealand
2Maurice Wilkins Centre for Molecular Biodiscovery, Auckland, New Zealand
3Department of Pathology, Dunedin School of Medicine, University of Otago, Dunedin, New Zealand
4Auckland Cancer Society Research Centre, University of Auckland, Auckland, New Zealand
Tóm tắt
AbstractMelanoma is a disease associated with a very high mutation burden and thus the possibility of a diverse range of oncogenic mechanisms that allow it to evade therapeutic interventions and the immune system. Here, we describe the characterization of a panel of 102 cell lines from metastatic melanomas (the NZM lines), including using whole‐exome and RNA sequencing to analyse genetic variants and gene expression changes in a subset of this panel. Lines possessing all major melanoma genotypes were identified, and hierarchical clustering of gene expression profiles revealed four broad subgroups of cell lines. Immunogenotyping identified a range of HLA haplotypes as well as expression of neoantigens and cancer–testis antigens in the lines. Together, these characteristics make the NZM panel a valuable resource for cell‐based, immunological and xenograft studies to better understand the diversity of melanoma biology and the responses of melanoma to therapeutic interventions.
